News
The “Top 10” list of best-selling gene therapies published by Genetic Engineering & Biotechnology News (GEN) in their May 2026 issue features three products based upon license agreements for technologies originating from the NIH Intramural Research Program. Featured and ranked on the GEN list are
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
1 in every 200 people with eye-related irritation in the US has uveitis. Vision loss can occur if the uveitis remains untreated, therefore, early detection is crucial. Certain uveitis cases currently require fluorescein angiography (FA) for diagnosis due to its ability to display retinal vascular